Loading...
Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!
- Ticker
- BNTX
- Price
- 91.06
- Stock movement down
- -3.89 (-4.10%)
- Company name
- BioNTech SE
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markkapitalisasie
- 21.83B
- Ondernemingswaarde
- 15.49B
- Prys/Verkope
- 7.18
- Prys/Boek
- 1.14
- Dividendopbrengs
- -
- Dividendgroei
- -
- Groei jare
- -
- FCF uitbetaling
- -
- Agterlopende P/E
- -
- Volgende P/E
- -
- PEG
- -
- EPS groei
- -
- 1 jaar opbrengs
- -2.05%
- 3 jaar opbrengs
- -18.85%
- 5 jaar opbrengs
- 14.05%
- 10 jaar opbrengs
- -
Laaste opgedateer: 2025-03-31
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDE
BNTX betaal nie dividende nie of geen data is ontvang nie
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
WAARDERING
Waarderingsverhoudings
Loading...
Waarderingsverhoudings gegewens
| Agterlopende P/E | - |
| Prys tot OCF | 14.34 |
| Prys tot FCF | 22.51 |
| Prys tot EBITDA | - |
| EV tot EBITDA | - |
Waardering (Verkope/Boekwaarde)
Loading...
Waardering (Verkope/Boekwaarde) gegewens
| Prys tot verkope | 7.18 |
| Prys tot Boekwaarde | 1.14 |
| EV tot verkope | 5.10 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANSIËLE
Per aandeel
Loading...
Per aandeel gegewens
| Huidige aandeeltelling | 239.74M |
| EPS (TTM) | -1.91 |
| FCF per aandeel (TTM) | 3.97 |
Inkomstestaat
Loading...
Inkomstestaat gegewens
| Inkomste (TTM) | 3.04B |
| Bruto wins (TTM) | 2.56B |
| Bedryfsinkomste (TTM) | -936.70M |
| Netto inkomste (TTM) | -466.90M |
| EPS (TTM) | -1.91 |
| EPS (1j vorentoe) | -3.34 |
Marges
Loading...
Marges gegewens
| Bruto marge (TTM) | 84.31% |
| Bedryfsmarge (TTM) | -30.81% |
| Winsgrens (TTM) | -15.36% |
Balansstaat
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
| Kontant | 9.62B |
| Netto debiteure | 1.20B |
| Totale bedryfsbates | 18.49B |
| Klandisiewaarde | 374.00M |
| Ontasbare bates | 873.90M |
| Eiendom, aanleg en toerusting | 1.16B |
| Totale bates | 22.40B |
| Rekeninge betaalbaar | 762.60M |
| Kort/huidige langtermynskuld | 243.70M |
| Totale bedryfslaste | 2.52B |
| Totale laste | 3.29B |
| Aandeelhouersbelang | 19.11B |
| Netto tasbare bates | 0.00 |
Kontantvloei
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
| Bedryfskontantvloei (TTM) | 1.52B |
| Kapitale uitgawes (TTM) | 551.93M |
| Vrye kontantvloei (TTM) | 969.97M |
| Dividende betaal (TTM) | 0.00 |
Finansiële opbrengste
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
| Opbrengs op ekwiteit | -2.44% |
| Opbrengs op bates | -2.08% |
| Opbrengs op belegde kapitaal | -2.41% |
| Kontant opbrengs op belegde kapitaal | 5.01% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
AANDELE INLIGTING
Aandele grafiek
Loading...
Aandele prys data
| Open | 89.00 |
| Daaglikse hoog | 91.56 |
| Daaglikse laag | 85.55 |
| Daaglikse volume | 2.31M |
| Hoogtepunt van alle tye | 447.23 |
| 1j analiseraaming | 137.65 |
| Beta | 0.26 |
| EPS (TTM) | -1.91 |
| Dividend per aandeel | - |
| Ex-dividend datum | 2 Jun 2022 |
| Volgende verdienste datum | 16 May 2025 |
Afwaartse potensiaal
Loading...
Afwaartse potensiaal gegewens
| BNTX | S&P500 | |
| Huidige prysdaling vanaf die hoogste punt van alle tye | -79.64% | -8.74% |
| Hoogste prysdaling | -82.48% | -56.47% |
| Datum van hoogste daling | 5 Aug 2024 | 9 Mar 2009 |
| Gemiddelde daling vanaf hoogtepunt | -52.00% | -11.07% |
| Gemiddelde tyd tot nuwe hoogtepunt | 24 days | 12 days |
| Maksimum tyd tot nuwe hoogtepunt | 915 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
MAATSKAPPY BESONDERHEDE
Markkapitalisasie
21.83B
Markkapitalisasie kategorie
Large-cap
Beskrywing
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Werknemers
6133
Webwerf
Beleggerverhoudings
-
SEC lêers
CEO
Ugur Sahin
Land
USA
Stad
Mainz
Aandele tipe
American depositary share
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Seeking AlphaPersvrystellings
iO Charts is a Seeking Alpha partnerVolgende bladsy